Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia.

Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, Huntington SF, Giri S, Gore SD, Ma X.

J Natl Compr Canc Netw. 2019 Mar 1;17(3):211-219. doi: 10.6004/jnccn.2018.7095.

PMID:
30865915
2.

Reply to H.J.A. Adams et al.

Huntington SF, von Keudell G, Davidoff AJ, Gross CP, Prasad SA.

J Clin Oncol. 2019 Feb 11:JCO1802297. doi: 10.1200/JCO.18.02297. [Epub ahead of print] No abstract available.

PMID:
30742563
3.

Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.

Bair SM, Strelec LE, Feldman TA, Ahmed G, Armand P, Shah NN, Singavi AN, Reddy N, Khan N, Andreadis C, Vu K, Huntington SF, Giri S, Ujjani C, Howlett C, Faheem M, Youngman MR, Nasta SD, Landsburg DJ, Schuster SJ, Svoboda J.

Oncologist. 2018 Dec 19. pii: theoncologist.2018-0538. doi: 10.1634/theoncologist.2018-0538. [Epub ahead of print]

PMID:
30568021
4.

The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera.

Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, Huntington SF, Giri S, Gore SD, Ma X.

Blood Adv. 2018 Oct 23;2(20):2681-2690. doi: 10.1182/bloodadvances.2018021436.

5.

Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma.

Huntington SF, von Keudell G, Davidoff AJ, Gross CP, Prasad SA.

J Clin Oncol. 2018 Oct 4:JCO1800122. doi: 10.1200/JCO.18.00122. [Epub ahead of print]

PMID:
30285558
6.

Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma.

Huntington SF, Hoag JR, Zhu W, Wang R, Zeidan AM, Giri S, Podoltsev NA, Gore SD, Ma X, Gross CP, Davidoff AJ.

Cancer. 2018 Nov 1;124(21):4211-4220. doi: 10.1002/cncr.31688. Epub 2018 Sep 14.

PMID:
30216436
7.

The changing face of adult posttransplant lymphoproliferative disorder: Changes in histology between 1999 and 2013.

Tsai DE, Bagley S, Reshef R, Shaked A, Bloom RD, Ahya V, Goldberg L, Chung A, Debonera F, Schuster SJ, Huntington SF.

Am J Hematol. 2018 Jul;93(7):874-881. doi: 10.1002/ajh.25116. Epub 2018 May 6.

PMID:
29659047
8.

R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis.

Shah NN, Szabo A, Huntington SF, Epperla N, Reddy N, Ganguly S, Vose J, Obiozor C, Faruqi F, Kovach AE, Costa LJ, Xavier AC, Okal R, Kanate AS, Ghosh N, Kharfan-Dabaja MA, Strelec L, Hamadani M, Fenske TS, Calzada O, Cohen JB, Chavez J, Svoboda J.

Br J Haematol. 2018 Feb;180(4):534-544. doi: 10.1111/bjh.15051. Epub 2017 Dec 19. Erratum in: Br J Haematol. 2018 Apr;181(1):152.

PMID:
29265182
9.

Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation.

Zeidan AM, Stahl M, Hu X, Wang R, Huntington SF, Podoltsev NA, Gore SD, Ma X, Davidoff AJ.

Blood. 2018 Feb 15;131(7):818-821. doi: 10.1182/blood-2017-10-811729. Epub 2017 Dec 19. No abstract available.

10.

Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study.

Zeidan AM, Long JB, Wang R, Hu X, Yu JB, Huntington SF, Abel GA, Mougalian SS, Podoltsev NA, Gore SD, Gross CP, Ma X, Davidoff AJ.

PLoS One. 2017 Sep 13;12(9):e0184747. doi: 10.1371/journal.pone.0184747. eCollection 2017.

11.

Health Care Use by Older Adults With Acute Myeloid Leukemia at the End of Life.

Wang R, Zeidan AM, Halene S, Xu X, Davidoff AJ, Huntington SF, Podoltsev NA, Gross CP, Gore SD, Ma X.

J Clin Oncol. 2017 Oct 20;35(30):3417-3424. doi: 10.1200/JCO.2017.72.7149. Epub 2017 Aug 7.

12.

Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation.

Hui L, von Keudell G, Wang R, Zeidan AM, Gore SD, Ma X, Davidoff AJ, Huntington SF.

Cancer. 2017 Oct 1;123(19):3763-3771. doi: 10.1002/cncr.30818. Epub 2017 Jun 22.

13.

Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study.

Zeidan AM, Hu X, Long JB, Wang R, Ma X, Podoltsev NA, Huntington SF, Gore SD, Davidoff AJ.

Cancer. 2017 Oct 1;123(19):3754-3762. doi: 10.1002/cncr.30814. Epub 2017 Jun 16.

14.

High-Cost, High-Value Oral Specialty Drugs: More Evidence on the Impact of Cost Sharing in Medicare Part D.

Huntington SF, Davidoff AJ.

J Clin Oncol. 2016 Dec 20;34(36):4307-4309. Epub 2016 Nov 14. No abstract available.

PMID:
27998230
15.

Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population-Based Study.

Wang R, Zeidan AM, Yu JB, Soulos PR, Davidoff AJ, Gore SD, Huntington SF, Gross CP, Ma X.

Prostate. 2017 Apr;77(5):437-445. doi: 10.1002/pros.23281. Epub 2016 Nov 21.

16.

Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes.

Zeidan AM, Davidoff AJ, Long JB, Hu X, Wang R, Ma X, Gross CP, Abel GA, Huntington SF, Podoltsev NA, Hajime U, Prebet T, Gore SD.

Br J Haematol. 2016 Dec;175(5):829-840. doi: 10.1111/bjh.14305. Epub 2016 Sep 21.

PMID:
27650975
17.

Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States.

Zeidan AM, Wang R, Gross CP, Gore SD, Huntington SF, Prebet T, Abel GA, Davidoff AJ, Ma X.

Leuk Lymphoma. 2017 Apr;58(4):982-985. doi: 10.1080/10428194.2016.1214954. Epub 2016 Aug 25. No abstract available.

PMID:
27558206
18.

High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia.

Doshi JA, Li P, Huo H, Pettit AR, Kumar R, Weiss BM, Huntington SF.

Am J Manag Care. 2016 Mar;22(4 Suppl):s78-86.

19.

Negative Studies in Cancer Research: Why the Negativity?

Huntington SF, Gross CP.

JAMA Oncol. 2016 Jul 1;2(7):865-6. doi: 10.1001/jamaoncol.2015.6540. No abstract available.

PMID:
26967116
20.

Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study.

Huntington SF, Weiss BM, Vogl DT, Cohen AD, Garfall AL, Mangan PA, Doshi JA, Stadtmauer EA.

Lancet Haematol. 2015 Oct;2(10):e408-16. doi: 10.1016/S2352-3026(15)00151-9. Epub 2015 Sep 17.

PMID:
26686042
21.

Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells.

Evans AG, Rothberg PG, Burack WR, Huntington SF, Porter DL, Friedberg JW, Liesveld JL.

Br J Haematol. 2015 Oct;171(2):205-209. doi: 10.1111/bjh.13562. Epub 2015 Jun 18.

PMID:
26084925
22.

Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission.

Huntington SF, Svoboda J, Doshi JA.

J Clin Oncol. 2015 May 1;33(13):1467-74. doi: 10.1200/JCO.2014.58.5729. Epub 2015 Mar 30.

PMID:
25823735
23.

Utility of interim and end-of-treatment [(18)F]-fluorodeoxyglucose positron emission tomography-computed tomography in frontline therapy of patients with diffuse large B-cell lymphoma.

Huntington SF, Nasta SD, Schuster SJ, Doshi JA, Svoboda J.

Leuk Lymphoma. 2015;56(9):2579-84. doi: 10.3109/10428194.2015.1007506. Epub 2015 Feb 11.

PMID:
25629993
24.

Toxicities and outcomes among septuagenarians and octogenarians with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy.

Huntington SF, Talbott MS, Greer JP, Morgan DS, Reddy N.

Leuk Lymphoma. 2012 Aug;53(8):1461-8. doi: 10.3109/10428194.2012.658793. Epub 2012 Mar 1.

PMID:
22260160

Supplemental Content

Loading ...
Support Center